Actually, in this Phase 2 for B-OM, the treatment is being evaluated as a preventative. That means that if it becomes the standard of care, it will be given to all of the targeted patients so as to prevent them from developing OM or to lesson its severity if it does develop.

I also think that it will cost much more than $500. There is currently an approved OM treatment for a small subset (5 to 10 percent) of the OM population. A poster some time back said that treatment is priced at $10,000. If that price is correct, treating 400,000 patients is a $4 billion dollar (per year) market.

But $75 million sounds good too...

Quote:

---

OM "....afflicts approximately 450,000 patients each year in the United States."

Let's say that 1/2 of them have it badly enough that treatment would be required. Let's say that a course of treatment averaged out to $500 each. 150,000x500 = 75 million. (and these figures are very modest estimates)

CTIX current market cap: 214.5 million.

Think about it, shorts, as you remove scgmk1's gift of Thanksgiving weenies from your
- Drano
Read More: investorshangout.com/post/view?id=3366091#ixzz3sZX92X1u

---